How will the proceeds from the private placement be allocated across the company's projects and operations?

Allocation of Proceeds

Acceleware’s extended private‑placement is intended to fund the next growth phase of its three core technology platforms – RF‑driven process‑heat for critical‑minerals extraction, amine‑regeneration systems for carbon‑capture, and RF‑enhanced oil‑recovery. Management has historically earmarked private‑placement capital for:

1. R&D & pilot‑scale deployment – expanding the test‑bed programs that validate RF‑power‑to‑heat performance on‑site, especially for lithium‑ and rare‑earth‑minerals projects where process‑heat is a bottleneck.
   
2. Commercialisation & field‑service rollout – scaling the amine‑regeneration unit to meet the burgeoning demand from CCS facilities in North America and Europe, and building the sales‑and‑service infrastructure needed for oil‑field contracts.
   
3. Working‑capital & balance‑sheet strengthening – a modest portion will be retained as liquidity to support ongoing operating expenses and to give the company a runway through the 2026‑27 capital‑expenditure window.

Trading Implications

The infusion of up‑to‑$X million (the exact tranche size was not disclosed) reduces financing risk and underwrites the capital‑intensive pilot programs that are the catalyst for future revenue. Assuming the company meets its development milestones, the equity‑base expansion should translate into higher‑margin contracts and a more resilient cash‑flow profile—an upside catalyst for the stock.

From a market‑technical perspective, the announcement removed a near‑term funding‑concern, which often triggers a short‑cover rally. If the price has already priced in the news, a modest pull‑back could create a buying opportunity on the dip, especially if the shares are still trading below the 20‑day moving average. Conversely, any delay in tranche closings or a shift in allocation toward working‑capital rather than project‑specific spend could dampen the upside.

Actionable Take‑away

- Short‑term: Look for a corrective bounce in the next 2‑3 trading days; consider a small‑position entry on a pull‑back to the 20‑day MA with a stop just below the recent low.

- Medium‑term: Track the company’s quarterly updates on pilot‑plant progress and amine‑regeneration contracts. Positive execution will likely fuel a sustained rally, while missed milestones could expose the stock to downside pressure.